A once-daily controlled-release formulation of MK-8189, a phosphodiesterase 10A inhibitor, achieves an optimal enzyme occupancy, pharmacokinetic profile and is well-tolerated
| Autor: | Khalilieh, S., Raybon, J., Mastroieni, T., Chain, A., Gertsik, L., Safirstein, B., Burkindine, D., Struyk, A., Stoch, A. |
|---|---|
| Zdroj: | In Neuroscience Applied 2023 2 Supplement 2 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|